Skip to main content

Table 2 ΔFMD

From: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

  Dapagliflozin group Metformin group P value
FMD (%)
 FAS population
  Baseline 4.80 ± 1.86 (37) 5.37 ± 2.95 (37) 0.33
  Week 16 5.66 ± 2.12 (37) 5.18 ± 2.09 (37) 0.33
  Change 0.85 ± 2.71 (37) −0.19 ± 2.51 (37) 0.09
  P value within group 0.06 0.65  
 Subpopulation: HbA1c at baseline <7.0%
  Baseline 4.72 ± 1.88 (24) 4.88 ± 2.76 (20) 0.83
  Week 16 5.47 ± 2.42 (24) 5.33 ± 2.23 (20) 0.85
  Change 0.75 ± 2.82 (24) 0.45 ± 2.48 (20) 0.71
  P value within group 0.21 0.43  
 Subpopulation: HbA1c at baseline ≥7.0%
  Baseline 4.95 ± 1.91 (13) 5.94 ± 3.14 (17) 0.30
  Week 16 6.01 ± 1.43 (13) 5.01 ± 1.96 (17) 0.12
  Change 1.05 ± 2.59 (13) −0.94 ± 2.39 (17) 0.041
  P value within group 0.17 0.13  
  1. Data are mean ± standard deviation (n). P values show results of comparisons between groups by t test. P values within groups are results of paired t test
  2. FAS full analysis set. See Table 1 for other abbreviations